Épisode 59: Étude SELECT
Épisode 59: Sémaglutide et protection cardiovasculaire chez les personnes avec obésité et maladie cardiovasculaire sans diabète (étude SELECT)
Diffusé le 18 décembre 2023
Dans cette 59e baladodiffusion, les Dr Luc Lanthier et Marie-France Langlois discutent de l’efficacité de sémaglutide pour réduire les événements cardiovasculaires chez les personnes avec obésité et maladie cardiovasculaire mais sans diabète, en plus de réviser la littérature médicale de novembre 2023.
Quiz clinique (2 min 19), présentation principale (2 min 48), critique (22 min 32), autres articles (33 min 10), réponse au quiz clinique (35 min 28)
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24): 2221-32. PubMed PMID: 37952131.
Khera A, Powell-Wiley TM. SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight. N Engl J Med. 2023;389(24):2287-2288. PubMed PMID: 37952130.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed PMID: 33567185.
Baig K, Dusetzina SB, Kim DD, Leech AA. Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. N Engl J Med. 2023;388(11):961-963. PubMed PMID: 36912541.
Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, et al. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023;402(10413):1627-35. PubMed PMID: 37640035.
Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023;402(10413):1636-47. PubMed PMID: 37863084.
Bendszus M, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial. Lancet. 2023;402(10414):1753-63. PubMed PMID: 37837989.
Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, et al; ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-1785. PubMed PMID: 37858323.
Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. N Engl J Med. 2023;389(21):1949-60. PubMed PMID: 37874020.
Carson JL, Stanworth SJ, Guyatt G, Valentine S, Dennis J, Bakhtary S, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA. 2023;330(19):1892-902. PubMed PMID: 37824153.
Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt CA, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. J Vasc Surg. 2023;78(5):1101-1131. PubMed PMID: 37724985.
Wood E, Bright J, Hsu K, Goel N, Ross JWG, Hanson A, et al. Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. CMAJ. 2023;195(40):E1364-E79. PubMed PMID: 37844924.
Maldonado JR, Sher Y, Ashouri JF, Hills-Evans K, Swendsen H, Lolak S, Miller AC. The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol. 2014 Jun;48(4):375-90. PubMed PMID: 24657098.
